ALBRIOZA Commercial Launch

HELIOS Phase 2 Study of AMX0035 in Wolfram syndrome 12 adult participants 24 weeks B Open-label study at the Washington University School of Medicine in St. Louis Primary Efficacy Outcomes Secondary Efficacy Outcomes First participant dosed in • C-peptide response • Visual acuity • • Safety and tolerability Exogenous insulin dose • Glucose range April 2023 Topline results anticipated in 2024 • HbA1c levels Orphan drug designation granted to AMX0035 for the treatment of Wolfram syndrome by U.S. FDA ✓ AMYLYX 32

View entire presentation